Eight stories could define the year for biotech investors

Eight stories could define the year for biotech investors


By most measures, biotech investors shouldn't have many gripes about the first half of 2017. The go-go years of 2013 and 2014 aren't making a roaring comeback, but our little corner of Wall Street has outperformed the broader market, despite the constant threat of D.C. meddling.



from Biotech News